9 February 2021
Chinese Sinovac Biotech announced that it has been granted a conditional marketing authorisation by the China National Medical Products Administration (NMPA) for CoronaVac, the company’s Covid-19 vaccine, for individuals aged over 18. The approval was granted on the basis of results from the company’s Phase III clinical trials, the efficacy and safety of which is yet to be confirmed.
Go deeper with GlobalData
Veru published positive data regarding a cancer drug’s potential in fighting the Covid-19 disease. The prostate cancer treatment achieved positive efficacy and safety data in the company’s Phase II clinical trial in hospitalised patients suffering from acute respiratory distress syndrome caused by Covid-19.
Reuters reports that Pakistan’s health minister confirmed that Chinese CanSino Biologics’ Covid-19 vaccine achieved 65.7% efficacy in preventing symptomatic cases in clinical trials. The vaccine also showed a 90.98% success rate in stopping severe disease in one of its interim analysis of global trials being carried out in Pakistan, Mexico, Russia, Argentina and Chile.
